欢迎来到范德生物BIOFOUNT
范德生物中国
范德生物产品购买购物车
0
搜索
157435-10-4
  • names:

    2-(4-((7-chloroquinoxalin-2-yl)oxy)phenoxy)propanoic acid

  • CAS号:

    157435-10-4

    MDL Number:
  • MF(分子式): C17H13ClN2O4 MW(分子量): 344.74912
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
XK469
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名 2-(4-((7-chloroquinoxalin-2-yl)oxy)phenoxy)propanoic acid
英文别名 XK469; XK 469; XK-469; NSC697887; NSC-697887; NSC 697887.
CAS号 157435-10-4
SMILES CC(OC1=CC=C(OC2=NC3=CC(Cl)=CC=C3N=C2)C=C1)C(O)=O
Inchi InChI=1S/C17H13ClN2O4/c1-10(17(21)22)23-12-3-5-13(6-4-12)24-16-9-19-14-7-2-11(18)8-15(14)20-16/h2-10H,1H3,(H,21,22)
InchiKey NUQZXROIVGBRGR-UHFFFAOYSA-N
分子式 Formula C17H13ClN2O4
分子量 Molecular Weight 344.74912
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状 Solid powder
储藏条件 Storage conditions Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).
产品说明 XK469(CAS:157435-10-4 ):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。
IntroductionXK489 is a synthetic quinoxaline phenoxypropionic acid derivative with proapoptotic and antiproliferative activities. R(+)XK469 selectively inhibits topoisomerase II-beta, blocks activation of MEK/MAPK signaling kinases, stimulates caspases, and upregulates p53-dependent proteins, including cyclins A and B1, thereby arresting cancer cells in the G2/M phase of the cell cycle. Both R(+) and S(-) isomers of this agent are cytotoxic, although the R-isomer is more potent.
Application1
Application2
Application3
警示图
危险性 Warning
危险性警示
安全声明
安全防护
备注
[1]Kakodkar NC, Peddinti R, Kletzel M, Tian Y, Guerrero LJ, Undevia SD, Geary D, Chlenski A, Yang Q, Salwen HR, Cohn SL. The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth. Pediatr Blood Cancer. 2011 Jan;56(1):164-7. doi: 10.1002/pbc.22639. PubMed PMID: 20860039.
[2]Yong WP, Kim TW, Undevia SD, Innocenti F, Ratain MJ. R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. Eur J Cancer. 2009 Jul;45(11):1904-8. doi: 10.1016/j.ejca.2009.04.032. Epub 2009 May 21. PubMed PMID: 19464879; PubMed Central PMCID: PMC2758059.
[3] Reiners JJ Jr, Kleinman M, Joiakim A, Mathieu PA. The chemotherapeutic agents XK469 (2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid) and SH80 (2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy}propionic acid) inhibit cytokinesis and promote polyploidy and induce senescence. J Pharmacol Exp Ther. 2009 Mar;328(3):796-806. doi: 10.1124/jpet.108.144808. Epub 2008 Dec 9. PubMed PMID: 19066341; PubMed Central PMCID: PMC2682258.
[4] Undevia SD, Innocenti F, Ramirez J, House L, Desai AA, Skoog LA, Singh DA, Karrison T, Kindler HL, Ratain MJ. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug;44(12):1684-92. doi: 10.1016/j.ejca.2008.05.018. Epub 2008 Jul 21. PubMed PMID: 18650079; PubMed Central PMCID: PMC2731567.
[5] Kessel D, Reiners JJ Jr, Hazeldine ST, Polin L, Horwitz JP. The role of autophagy in the death of L1210 leukemia cells initiated by the new antitumor agents, XK469 and SH80. Mol Cancer Ther. 2007 Jan;6(1):370-9. PubMed PMID: 17237296; PubMed Central PMCID: PMC2877038.
6: Alousi AM, Boinpally R, Wiegand R, Parchment R, Gadgeel S, Heilbrun LK, Wozniak AJ, DeLuca P, LoRusso PM. A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. Invest New Drugs. 2007 Apr;25(2):147-54. Epub 2006 Nov 11. PubMed PMID: 17103044.7: Hazeldine ST, Polin L, Kushner J, White K, Corbett TH, Horwitz JP. Synthesis and biological evaluation of conformationally constrained analogs of the antitumor agents XK469 and SH80. Part 5. Bioorg Med Chem. 2006 Apr 1;14(7):2462-7. Epub 2005 Dec 5. PubMed PMID: 16337128.8: Hazeldine ST, Polin L, Kushner J, White K, Corbett TH, Horwitz JP. Synthetic modification of the 2-oxypropionic acid moiety in 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469), and consequent antitumor effects. Part 4. Bioorg Med Chem. 2005 Jun 2;13(12):3910-20. PubMed PMID: 15911307.9: Anderson LW, Collins JM, Klecker RW, Katki AG, Parchment RE, Boinpally RR, LoRusso PM, Ivy SP. Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions. Cancer Chemother Pharmacol. 2005 Oct;56(4):351-7. Epub 2005 May 13. PubMed PMID: 15895233.10: Boinpally RR, Zhou SL, LoRusso PM, Parchment RE. Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration. Cancer Chemother Pharmacol. 2005 Apr;55(4):404-7. Epub 2004 Dec 9. PubMed PMID: 15592839.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻

        怎么做细胞爬片免疫组化染色实验

        细胞爬片免疫组化染色,是通过细胞爬片是让玻片浸在细胞培养基内,细胞在玻片上生长,主要用于组织学,免疫组织化学...

        2020/7/20 22:04:33

        提取病毒RNA的实验方法

        提取病毒RNA方法分别有:异硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...

        2020/7/22 20:29:26

        Waxfilm 实验室封口膜:技术与国际市场的双重突破

        在实验室耗材领域,封口膜是保障实验准确性与稳定性的关键产品之一。近年来,Waxfilm?实验室封口膜凭借其卓...

        2025/5/13 13:03:40

        Waxfilm实验室封口膜的5大突破

        Waxfilm实验室封口膜作为生物功能膜领域的国产技术突破和品牌突破,是生物领域中国技术发展的缩影。

        2025/5/6 17:02:07

        各种微流控芯片键合方法的优缺点

        微流控芯片键合:目前主要有激光焊接、热压键合、胶键合、超音波焊接,每种方法都有各自的优缺点。本文主要介绍聚酯...

        2023/7/28 10:43:09

        新一代微流控键合解决方案

        微流控键合解决方案:微流控芯片制造的一个重要环节,也是最容易被忽视的--芯片键合。其中一个重要因素是:微流控...

        2023/7/27 12:44:28

        荧光素钾盐使用说明

        D-荧光素钾盐(K+)设计用于体外和体内生物发光测定。D-荧光素的质量和纯度对于获得良好和可重复的结果至关重...

        2023/7/20 11:05:11

        如何选BSA(牛血清白蛋白)

        如何选BSA(牛血清白蛋白):牛血清白蛋白(BSA)有多种形式,如何选择适合自己的牛血清白蛋白(BSA)是一...

        2023/2/14 13:09:18

        牛血清白蛋白(BSA)常见问题

        牛血清白蛋白(BSA)常见问题:牛血清白蛋白(BSA)在实验室中是通用的,可用于蛋白质印迹、细胞组织培养、P...

        2022/10/19 9:39:51

        pubmed使用方法(技巧)

        pubmed使用方法(技巧):PubMed是一个关于医学问题的学术文章和书籍的数据库。因为它是一份学术期刊,...

        2022/10/18 18:06:07

        My title page contents